NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCR NovoCure

Closed Good Friday 04-17 16:00:00 EDT

15.58

-0.25

-1.58%

盘后15.58

+0.000.00%

16:32 EDT

High15.85	Low15.52	Vol705.58K
Open15.74	D1 Closing15.83	Amplitude2.12%
Mkt Cap1.71B	Tradable Cap1.47B	Total Shares109.92M
T/O11.03M	T/O Rate0.75%	Tradable Shares94.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"NVCR","market":"US","secType":"STK","nameCN":"NovoCure","latestPrice":15.58,"timestamp":1744920000000,"preClose":15.83,"halted":0,"volume":705577,"hourTrading":{"tag":"盘后","latestPrice":15.58,"preClose":15.58,"latestTime":"16:32 EDT","volume":14550,"amount":226689.27,"timestamp":1744921962618},"delay":0,"floatShares":94502219,"shares":109915429,"eps":-1.563759,"marketStatus":"Closed Good Friday","change":-0.25,"latestTime":"04-17 16:00:00 EDT","open":15.74,"high":15.85,"low":15.515,"amount":11031573.624602001,"amplitude":0.021162,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.563759,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1443758400000,"exchange":"NASDAQ","adjPreClose":15.83,"preHourTrading":{"tag":"盘前","latestPrice":15.51,"preClose":15.83,"latestTime":"04:37 EDT","volume":2,"amount":31.380002,"timestamp":1744879038569},"postHourTrading":{"tag":"盘后","latestPrice":15.58,"preClose":15.58,"latestTime":"16:32 EDT","volume":14550,"amount":226689.27,"timestamp":1744921962618},"volumeRatio":0.9999000384936468,"impliedVol":0.8261,"impliedVolPercentile":0.8167},"requestUrl":"/m/hq/s/NVCR","defaultTab":"news","newsList":[{"id":"2528638728","title":"NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?","url":"https://stock-news.laohu8.com/highlight/detail?id=2528638728","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528638728?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 22:01","pubTimestamp":1744898473,"startTime":"0","endTime":"0","summary":"The market expects NovoCure  to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on April 24, 2025, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.Revenues are expected to be $148.25 million, up 7% from the year-ago quarter.Please note that a negative Earnings ESP reading is not indicative of an earn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novocure-nvcr-expected-beat-earnings-140113494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVCR"],"gpt_icon":0},{"id":"2528726622","title":"Why NovoCure Stock Was Withering on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2528726622","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528726622?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 03:43","pubTimestamp":1744832580,"startTime":"0","endTime":"0","summary":"A price target reduction from an analyst wasn't significant, but exacerbated the bearish sentiment on the company.Investors shouldn't throw in the towel yet, though.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/16/why-novocure-stock-was-withering-on-wednesday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4534","BK4585","NVCR","BK4082","BK4588","BK4548"],"gpt_icon":0},{"id":"2527624167","title":"Novocure Is Maintained at Neutral by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2527624167","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527624167?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 22:18","pubTimestamp":1744813080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 10:18 ET (14:18 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"gpt_icon":0},{"id":"2526756002","title":"Novocure Is Maintained at Neutral by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2526756002","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526756002?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 21:51","pubTimestamp":1744293060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2025 09:51 ET (13:51 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"gpt_icon":0},{"id":"2526598097","title":"Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526598097","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526598097?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:40","pubTimestamp":1744288800,"startTime":"0","endTime":"0","summary":"Bio-Techne TECH shares ended the last trading session 10.8% higher at $54.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 16.5% loss over the past four weeks.Bio-Techne scored a strong price increase on investors’ optimism surrounding its impending fiscal 2025 third-quarter financial results, expected to release on May 7 before the opening bell. In the last reported second quarter, both the top and bottom lines surpassed the Zacks Consensus Estimate by 4.1% and 10.5%, respectively.This maker of medical testing and diagnostic products is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of +8.3%. Revenues are expected to be $316.3 million, up 4.2% from the year-ago quarter.For Bio-Techne, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep movin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-bio-techne-tech-124000928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","TECH","IE00B64QTZ34.USD","BK4548","BK4082","IE0034390439.USD","IE00B19Z6F94.USD","BK4585","BK4588","NVCR","BK4534"],"gpt_icon":0},{"id":"2526843078","title":"NovoCure (NASDAQ:NVCR investor three-year losses grow to 80% as the stock sheds US$133m this past week","url":"https://stock-news.laohu8.com/highlight/detail?id=2526843078","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526843078?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 21:49","pubTimestamp":1744120194,"startTime":"0","endTime":"0","summary":"Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So spare a thought for...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nasdaqnvcr-investor-three-year-losses-grow-to-80-as","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4534","LU2095319765.USD","PSQ","BK4548","IE00B3QW5Z07.USD","BK4585","USAW.SI","QID","BK4112","LU2210149790.SGD","BK4082","TQQQ","NDAQ","TSYW.SI","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","NVIW.SI","BK4588","SQQQ","MNQmain","IE00B64PRP62.GBP",".IXIC","QLD","NQmain","USJW.SI","NVCR"],"gpt_icon":1},{"id":"2524235194","title":"Press Release: Novocure to Report First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524235194","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524235194?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:10","pubTimestamp":1743505800,"startTime":"0","endTime":"0","summary":"Novocure  will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company's financial results for the three-month quarter that ended March 31, 2025.To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4534","NVCR","BK4548","BK4082"],"gpt_icon":0},{"id":"2524191096","title":"Novocure to Report First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524191096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524191096?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:00","pubTimestamp":1743505202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUAB75PTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","NVCR","BK4585","BK4082","BK4548","BK4588"],"gpt_icon":0},{"id":"2517522130","title":"Wells Fargo Sticks to Its Buy Rating for NovoCure (NVCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517522130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517522130?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 18:36","pubTimestamp":1741257398,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Larry Biegelsen maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of $40.00. Accord...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-novocure-nvcr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-novocure-nvcr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCR"],"gpt_icon":0},{"id":"2516620410","title":"Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516620410","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516620410?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"BAAR, Switzerland, March 04, 2025----Novocure  announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event.Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novocure-participate-leerink-partners-2025-120000348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","HCSG","BK4588","BK4137","BK4548","BK4082","BK4585","NVCR"],"gpt_icon":0},{"id":"1149436505","title":"Stock Track | NovoCure Plummets 5.3% as EPS Misses Expectations in Full-Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1149436505","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149436505?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 22:49","pubTimestamp":1740754161,"startTime":"0","endTime":"0","summary":"NovoCure Ltd. , a global oncology company, saw its stock plummet 5.3% in the intraday trading session on Friday, following the release of its full-year 2024 earnings results.The company reported revenue of $605.2 million for the fiscal year 2024, up 19% year-over-year and in line with analyst estimates. However, NovoCure's earnings per share  fell short of expectations, missing by 20% at a loss of $1.56 per share.The EPS miss appears to have weighed heavily on investor sentiment, as the company'","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | NovoCure Plummets 5.3% as EPS Misses Expectations in Full-Year 2024 Results","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NVCR"],"gpt_icon":0},{"id":"2514034167","title":"NovoCure Full Year 2024 Earnings: EPS Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514034167","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514034167?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 18:07","pubTimestamp":1740737253,"startTime":"0","endTime":"0","summary":"NasdaqGS:NVCR Earnings and Revenue Growth February 28th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue was in line with analyst estimates. Earnings per share  missed analyst estimates by 20%.Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.The company's shares are down 11% from a week ago.We should say that we've discovered 2 warning signs for NovoCure that you should be aware of before investing here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novocure-full-2024-earnings-eps-100733199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVCR"],"gpt_icon":0},{"id":"2514313175","title":"NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2514313175","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514313175?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 15:09","pubTimestamp":1740726554,"startTime":"0","endTime":"0","summary":"Revenue : $161 million, a 21% increase compared to Q4 2023.Revenue : $605 million, a 19% increase year-over-year.Gross Margin : 77%, up from 75% in 2023.Net Loss : $169 million or $1.56 per share.Adjusted EBITDA : $3 million, an increase of $34 million from Q4 2023.GuruFocus has detected 4 Warning Signs with NVCR.For the complete transcript of the earnings call, please refer to the full earnings call transcript.NovoCure Ltd  achieved FDA approval for the treatment of non-small cell lung cancer, expanding its market reach beyond glioblastoma.NovoCure Ltd  grew its global active patient count to over 4,000, marking a 10% increase.The company has a strong cash position with $960 million in cash and cash equivalents, providing financial stability for future growth initiatives.Reimbursement negotiations for the new lung cancer indication are ongoing, with material revenue expected to ramp up only in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novocure-ltd-nvcr-q4-2024-070914831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVCR"],"gpt_icon":0},{"id":"2514590337","title":"NovoCure (NVCR) Q4 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2514590337","media":"Motley Fool Transcribing","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514590337?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 04:30","pubTimestamp":1740688232,"startTime":"0","endTime":"0","summary":"NVCR earnings call for the period ending December 31, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2025/02/27/novocure-nvcr-q4-2024-earnings-call-transcript/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["NVCR"],"gpt_icon":0},{"id":"2514331478","title":"NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514331478","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514331478?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 03:33","pubTimestamp":1740684797,"startTime":"0","endTime":"0","summary":"NovoCure&#39;s Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio&#39;s expansion.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/44020678/novocure-reports-wider-than-expected-q4-quarterly-loss-despite-clocking-21-jump-in-sales-expects-lower-gross-margin-in-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"gpt_icon":0},{"id":"2514238004","title":"Analysts Are Bullish on Top Healthcare Stocks: NovoCure (NVCR), Altimmune (ALT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514238004","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514238004?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 01:00","pubTimestamp":1740675653,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NovoCure (NVCR – Research Report) and Altimmune (ALT...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-novocure-nvcr-altimmune-alt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-novocure-nvcr-altimmune-alt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","ALT","BK4548","HCSG","BK4137","LU1878469433.USD","NVCR","BK4585","BK4082","BK4599","BK4588","BK4139"],"gpt_icon":0},{"id":"2514438776","title":"Novocure Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2514438776","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514438776?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 00:45","pubTimestamp":1740674756,"startTime":"0","endTime":"0","summary":"Novocure Ltd reports results for the quarter ended December 31 - Earnings SummaryNovocure Ltd NVCR.OQ reported a quarterly adjusted loss of 61 cents per share for the quarter ended December 31, lower ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI2MA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"gpt_icon":0},{"id":"2514382083","title":"NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382083","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514382083?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 23:00","pubTimestamp":1740668402,"startTime":"0","endTime":"0","summary":"NovoCure  reported $161.27 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 20.6%. EPS of -$0.61 for the same period compares to -$0.45 a year ago.The reported revenue represents a surprise of -0.02% over the Zacks Consensus Estimate of $161.3 million. With the consensus EPS estimate being -$0.34, the EPS surprise was -79.41%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how NovoCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:. Net revenues- United States: $107.20 millio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novocure-nvcr-reports-q4-earnings-150002262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVCR"],"gpt_icon":0},{"id":"1159153567","title":"Stock Track | NovoCure Stock Plummets 8.38% in Pre-Market as Wider Q4 Loss Offsets Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1159153567","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159153567?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 22:41","pubTimestamp":1740667295,"startTime":"0","endTime":"0","summary":"NovoCure Ltd. , a leading oncology treatment company, saw its stock price plummet by 8.38% in the pre-market trading session on Thursday, following the release of its mixed fourth-quarter 2024 earnings report.While the company reported a 21% year-over-year increase in revenue, reaching $161.3 million and matching analyst expectations, its profitability took a hit due to higher expenses. NovoCure reported a wider net loss of $0.61 per diluted share for the quarter, significantly worse than the ex","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NVCR"],"gpt_icon":0},{"id":"1191595126","title":"Stock Track | NovoCure Plunges 6.4% in Pre-Market Trading as Q4 Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=1191595126","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191595126?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 22:31","pubTimestamp":1740666696,"startTime":"0","endTime":"0","summary":"NovoCure Ltd , a leading oncology treatment company, saw its stock price plunge by 6.4% during pre-market trading on Thursday morning. This decline was driven by the company's mixed fourth-quarter earnings report, where it reported a wider net loss compared to the previous year, despite revenue growth meeting analyst expectations.The key factor contributing to the stock's decline was NovoCure's reported net loss of $0.61 per diluted share for the fourth quarter of 2024, significantly worse than ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NVCR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novocure.com","stockEarnings":[{"period":"1week","weight":-0.0311},{"period":"1month","weight":-0.1952},{"period":"3month","weight":-0.4047},{"period":"6month","weight":-0.0947},{"period":"1year","weight":0.2929},{"period":"ytd","weight":-0.4772}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":-0.024854},{"month":2,"riseRate":0.4,"avgChangeRate":-0.01214},{"month":3,"riseRate":0.5,"avgChangeRate":-0.017692},{"month":4,"riseRate":0.4,"avgChangeRate":0.065187},{"month":5,"riseRate":0.777778,"avgChangeRate":0.143619},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.022202},{"month":7,"riseRate":0.555556,"avgChangeRate":0.033773},{"month":8,"riseRate":0.555556,"avgChangeRate":0.014898},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.029067},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.10093},{"month":11,"riseRate":0.7,"avgChangeRate":0.085037},{"month":12,"riseRate":0.5,"avgChangeRate":0.070759}],"exchange":"NASDAQ","name":"NovoCure","nameEN":"NovoCure"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NovoCure,NVCR,NovoCure股票,NovoCure股票老虎,NovoCure股票老虎国际,NovoCure行情,NovoCure股票行情,NovoCure股价,NovoCure股市,NovoCure股票价格,NovoCure股票交易,NovoCure股票购买,NovoCure股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction